SCM
HRTX icon

Sterling Capital Management’s Heron Therapeutics HRTX Stock Holding History

Sterling Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344 Sell
807
-3,820
-83% -$3.06K ﹤0.01% 3246
2026
Q1 		$3.7K Sell
4,627
-3,349
-42% -$3.88K ﹤0.01% 2832
2025
Q4 		$10.4K Sell
7,976
-1,438
-15% -$1.77K ﹤0.01% 2588
2025
Q3 		$11.9K Buy
9,414
+5,720
+155% +$9.07K ﹤0.01% 2396
2025
Q2 		$7.65K Buy
3,694
+1,848
+100% +$3.77K ﹤0.01% 2288
2025
Q1 		$4.06K Sell
1,846
-1,778
-49% -$3.45K ﹤0.01% 2268
2024
Q4 		$5.54K Buy
3,624
+3,275
+938% +$5.31K ﹤0.01% 2433
2024
Q3 		$695 Buy
+349
New +$833 ﹤0.01% 2718

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Sterling Capital Management's HRTX Position: Q2 2026 in Review

Sterling Capital Management reduced its Heron Therapeutics (HRTX) stake by 83% in Q2 2026, selling an estimated $3.06K and leaving 807 shares worth $344. The position accounts for ﹤0.01% of the portfolio, ranked #3246.

Sterling Capital Management first reported a position in HRTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.9K in Q3 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Sterling Capital Management held 807 shares of Heron Therapeutics worth $344 as of Q2 2026.
  • Sterling Capital Management sold 3,820 Heron Therapeutics shares in Q2 2026, an estimated $3.06K.
  • Heron Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3246 holding.
  • Sterling Capital Management first reported a position in Heron Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Heron Therapeutics position peaked at $11.9K in Q3 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.